Non-inferiority of simplified dolutegravir monotherapy compared to continued combination antiretroviral therapy that was initiated during primary HIV infection: a randomized, controlled, multi-site, open-label, non-inferiority trial
ContributorsBraun, Dominique L; Turk, Teja; Tschumi, Fabian; Grube, Christina; Hampel, Benjamin; Depmeier, Carsten; Schreiber, Peter W; Brugger, Silvio D; Greiner, Michael; Steffens, Daniela; de Torrenté-Bayard, Cornelia; Courlet, Perrine; Neumann, Kathrin; Kuster, Herbert; Flepp, Markus; Bertisch, Barbara; Decosterd, Laurent; Böni, Jürg; Metzner, Karin J; Kouyos, Roger D; Günthard, Huldrych F
Published inClinical Infectious Diseases, vol. 69, no. 9, p. 1489-1497
Publication date2019
Abstract
Keywords
- Primary HIV infection
- Dolutegravir
- Monotherapy
- Simplification
- Randomized controlled trial
Research group
Funding
- Swiss National Science Foundation - 179571
- Swiss National Science Foundation - Combining molecular epidemiology approaches and mathematical models for the spread of HIV and its coinfections [PZ00P3_142411]
- Swiss National Science Foundation - Using transmission networks for assessing and guiding prevention efforts in hiv [BSSGI0_155851]
- Swiss National Science Foundation - Modélisation, Simulation et Validation clinique des Interactions Médicamenteuses dans la Swiss HIV Cohort Study [324730_165956]
Citation (ISO format)
BRAUN, Dominique L et al. Non-inferiority of simplified dolutegravir monotherapy compared to continued combination antiretroviral therapy that was initiated during primary HIV infection: a randomized, controlled, multi-site, open-label, non-inferiority trial. In: Clinical Infectious Diseases, 2019, vol. 69, n° 9, p. 1489–1497. doi: 10.1093/cid/ciy1131
Main files (2)
Article (Accepted version)
Article (Published version)
Identifiers
- PID : unige:125267
- DOI : 10.1093/cid/ciy1131
- PMID : 30601950
Commercial URLhttps://academic.oup.com/cid/article/69/9/1489/5269466
ISSN of the journal1058-4838
